skip to main content
Global Search Configuration

Biosimilars – commercial best practices in the age of sustainability

See how biosimilars are the leading growth engine of global medicines spending:

  • Revenues from biologics increased by 70% from 2011 to 2016
  • Biologics account for 20-22% of total pharmaceutical spending
  • IQVIA estimates US biologics spending will reach $320bn by 2023

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: